MedTrace Logo

Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson's Disease

NCT03959540 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 39

Last updated 2021-10-04

No results posted yet for this study

Summary

The purpose of this study is to describe the safety and efficacy of opicapone plus standard of care in elderly patients with PD in the real-world setting

Conditions

  • Parkinson Disease

Interventions

DRUG

Opicapone

Capsules, oral use - 50 mg Use of opicapone is only driven by the physician's decision.

DRUG

Levodopa (L-DOPA) + Standard care

Levodopa (immediate- or controlled-release) + Standard care. Use of Levodopa and standard of care are only driven by the physician's decision.

Sponsors & Collaborators

  • Bial - Portela C S.A.

    lead INDUSTRY

Eligibility

Min Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-28
Primary Completion
2021-05-11
Completion
2021-05-11

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03959540 on ClinicalTrials.gov